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In order to gain a better perspective on the true variability of varicella–zoster virus (VZV) and to catalogue the location and number of
differences, 11 new complete genome sequences were compared with those previously in the public domain (18 complete genomes in total). Three
of the newly sequenced genomes were derived from a single strain in order to assess variations that can occur during serial passage in cell culture.
The analysis revealed that while VZV is relatively stable genetically it does posses a certain degree of variability. The reiteration regions, origins of
replication and intergenic homopolymer regions were all found to be variable between strains as well as within a given strain. In addition, the
terminal viral sequences were found to vary within and between strains specifically at the 3′ end of the genome. Analysis of single nucleotide
polymorphisms (SNPs) identified a total of 557 variable sites, 451 of which were found in coding regions and resulted in 187 different in amino
acid substitutions. A comparison of the SNPs present in the two gE mutant strains, VZV-MSP and VZV-BC, suggested that the missense mutation
in gE was primarily responsible for the accelerated cell spread phenotype. Some of the variations noted with high passage in cell culture are
consistent with variations seen in the IE62 gene of the vaccine strains (S628G, R958G and I1260V) that may help in pinpointing variations
essential for attenuation. Although VZV has been considered to be one of the most genetically stable human herpesviruses, this initial assessment
of genomic VZV cartography provides insight into ORFs with previously unreported variations.
© 2006 Elsevier Inc. All rights reserved.Keywords: Genomics; Varicella-zoster virus; VZV; Phylogeny; Recombination; GenotypeIntroduction
VZV has long been known to be a genetically stable virus.
However, in 1995 a VZV strain with a mutated gE protein was
isolated from a child in Minnesota (Santos et al., 1998). Four
years later, a very similar strain with a mutated gE protein was
obtained from an elderly man with zoster, who lived in
Vancouver, Canada (Tipples et al., 2002). In these strains the⁎ Corresponding author. National Microbiology Laboratory, Public Health
Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E
3R2. Fax: +1 204 789 5009.
E-mail address: Graham_Tipples@phac-aspc.gc.ca (G.A. Tipples).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.09.037gE mutation abrogated a B cell epitope defined by the 3B3
monoclonal antibody (mAb) and these viruses were also found
to exhibit a faster cell spread phenotype (Santos et al., 2000). In
other words, the gE mutant viruses were a new genotype and
defined a second serotype. At the International Herpesvirus
Workshop in 2005, virologists from Stockholm, Sweden,
reported the discovery of 2 additional gE mutant viruses
(Wirgart et al., 2006). These strains possessed identical
mutations that differed from the previously described strains
but still affected the epitope targeted by mAb 3B3. The first two
gEmutant viruses have been completely sequenced (Grose et al.,
2004) and our expectation was that the viruses would be
essentially identical at the genetic level and prove to represent a
448 S.D. Tyler et al. / Virology 359 (2007) 447–458single circulating subpopulation of the virus although the
epidemiology of the isolates suggested that they may have
arisen independently (Tipples et al., 2002). However, even
though the viruses were very similar they were found to posses
sufficient differences that made it likely they were not directly
related phylogenetically (Grose et al., 2004).
A number of previous studies have examined genetic
variation in VZV (Argaw et al., 2000; Barrett-Muir et al.,
2001, 2003; Faga et al., 2001; Hawrami et al., 1997; LaRussa et
al., 1992, 1998; Loparev et al., 2004; Quinlivan et al., 2002;
Takada et al., 1995; Wagenaar et al., 2003). Regions of the
genome noted to display variability between isolates were
primarily restricted to the five reiteration regions; additionally a
number of scattered SNPs were identified across the genome,
some of which result in restriction enzyme recognition site
changes. Of these changes, ORF 62 SmaI, ORF 38 PstI and
ORF 54 BglI have been primarily used to distinguish between
circulating wild-type isolates and the attenuated Oka vaccine
derivatives. The complete genomic sequences of the Oka
parental and vaccine strains have been determined (Gomi et al.,
2002; Vassilev, 2005), but based solely on the DNA sequences
the mechanism of attenuation is not yet fully elucidated. The
majority of the nucleotide differences identified were in IE62,
the immediate–early transactivator protein, with other coding
mutations scattered throughout the genome.
Studies to characterize the live attenuated varicella vaccine
have demonstrated that the vaccine virus replicates more slowly
than wild-type virus (Moffat et al., 1998) and that the attenuated
virus has acquired new attributes. For example, the vaccine
virus, v-Oka, was attenuated by serial passage in guinea pig
cells and therefore replicates better in guinea pig cells than its
parental stock (Takahashi, 1984). Based on the insight gained
from the full genome analysis of the gE mutant viruses, we
postulated that a similar genomic analysis of multiple VZV
strains would prove useful in defining the extent of variation
that is truly present among VZV strains with the ultimate goal of
providing insight into the genetic nature of attenuation. To that
end our study included a VZV strain which was serially
passaged 72 times in order to determine whether similar genetic
changes would occur as were found in the vaccine VZV strains
which were also derived by serial passage in cell culture. With
the addition of these genomic sequences to the data pool, there
now exist sufficient information to begin to assess VZV
genomic cartography.
Results
As was expected the genomic sequences for the 11 new
strains of VZV determined in this study were found to be
highly similar to those previously reported with an overall
nucleotide identity of >99.7% (discounting insertions and
deletions) for the 18 strains analyzed. The genome sizes were
ca. 125 kbp and the overall genome structure and organiza-
tion was identical to the accepted arrangement for the major
isoform of these viruses. Phylogenetic and recombination
aspects of this genomic comparison study are described by
Peters et al. (2006).Genomic termini
In compiling the complete full-length sequences of the
isolates, the terminal sequences obtained by amplifying the
junction between ORF 0 and ORF 62 from replicating virus
DNA were found to be highly variable with the point of
variability corresponding to the junction point between the 5′
and 3′ ends of the genome. In order to explore these differences
further, the individual termini were specifically targeted from
linear nucleocapsid DNA.
The sequence analysis of the termini obtained in this manner
showed that the left genomic terminus (containing the pac2
packaging signal) was conserved among all the strains
examined in this study, although the terminus lacked the last
adenine residue reported in previous work on the Dumas strain
(Davison, 1984; Davison and Scott, 1986). In contrast, clones of
the right terminus showed considerable length heterogeneity
(up to 70 bp). The number of clones sequenced was insufficient
to provide a comprehensive analysis of the differences;
however, the degree of variability did not appear to be strain
specific and was observed among clones derived from the same
strain. Some of the clones of the right terminus lacked the pac1
signal necessary for packaging and were therefore likely part of
non-functional genomes. This imprecision in the cleavage of the
terminus adjacent to the pac1 signal has been previously
reported for the cleavage of HHV-6 (Deng and Dewhurst, 1998)
and it has been shown in other herpesviruses that intra-strain
variability in the number of terminal repeats occurs at one
terminus but not the other (Davison andWilkie, 1981; McVoy et
al., 1998; Thomson et al., 1994; Tyler et al., 2005).
Strain-independent heterogeneity was also observed at the
internal junction between the long and short regions of the VZV
genome. PCR clones targeting this region revealed that while
some intra-strain variation was present it was not as extensive as
what was seen at the terminal junction and the majority of the
clones sequenced for a given strain corresponded to the
consensus that is presented in the full genome sequences.
Origin of replication
The central region of the origin of replication was found to
be quite variable between the strains and is illustrated in Fig. 1.
A basic motif of TA(N)GA(N) was characteristic of this region
but the strains differed in the number of TA and GA repeats they
contained. Where sequence data were available from multiple
independent clones for the ORI region of a particular strain it
was also noted that this TA/GA motif could be variable within a
strain. For some strains the variation appeared to be restricted to
the number of TA units present while in other strains both the
number of TA and GA units were variable. However, it should
be noted that the sequence redundancy in this region was not
extensive for all of the strains. In some cases 8 to 10 individual
sequences were available for a given strain, whereas others were
only covered by 2 or 3 clones. Therefore, any bias in the type of
intra-strain variation observed could simply be due to a lack of
suitable sampling. However, the extent of variation within a
given strain did not appear to be as extensive as what was noted
Fig. 1. Comparison of the origin of replication among VZV strains. The sequence depicted corresponds to 110,166–110,263 bp of the Dumas sequence. Gaps in the
alignment are noted with a dash (-) and variable sites are highlighted. VarilRix2 and VariVax2 are the sequences of the ORI as reported for the terminal inverted repeat
for the respective strains. All other sequences were reported or found to have identical ORI sequences in both copies. The “K” substitution in VariVax2 denotes a G/T
polymorphic site reported for this sequence.
449S.D. Tyler et al. / Virology 359 (2007) 447–458between the strains, even for those that had a high sequencing
redundancy in this region. The sequences presented in Fig. 1
represent what was determined as the consensus sequence for
the individual strains and reflects the form that was most
frequently observed.
VarilRix and VariVax are reported as having two different
forms of the ORI sequence in the different copies of the inverted
repeats. In IRS the ORI is similar in type to pOka and vOka, but
in TRS a G/A substitution has occurred in the GA(N) motif
which reverted it to the form found in all other strains examined.
Due to the sequencing strategies used for many of the strains in
this study it was not always possible to assign the source of the
ORI sequence as belonging to one repeat or the other; but in all
cases where multiple sequences were available for this region
from a particular strain, this type of variation was not seen and
only that noted for the TA/GA motif was observed.
In addition to the variations depicted in Fig. 1 an additional
G/A polymorphism was noted corresponding to 110,112 bp of
the Dumas sequence for pOka and vOka as previously described
(Gomi et al., 2002). This SNP was also identified in VarilRix
and VariVax and may be indicative of the common origin of
these strains. VZV-8 harbored a unique T/G polymorphism in
the ORI region. Downstream of the core ORI region, tandem G/
A polymorphisms corresponding to 110,325 and 110,326 bp of
the Dumas sequence were also noted for VZV-11, VZV-22 and
VZV-03-500. As the ORI is located in the inverted repeat, these
differences were also noted in the corresponding regions of the
terminal copy of the repeat.
A more detailed analysis of variation related to the origin of
replication was extended to include all of the genes associated
with the replication complex and the specific variations noted
are summarized in Table 1. While some variation was noted in
all of these genes in at least one of the strains, the only variations
of potential interest were found in ORFs 6, 52 and 55, which
constitute the trimeric helicase–primase complex. These genes
consistently possessed variations that were found in the vaccine
strains but not in pOka, although the mutations resulted in either
polymorphic substitutions or were not universally found in all
of the vaccine strains.Reiteration regions
Comparison of the newly sequenced genomes of these
strains with those previously described (Davison and Scott,
1986; Gomi et al., 2002; Grose et al., 2004; Vassilev, 2005)
showed that a certain degree of strain-to-strain variability was
common despite the overall stability of the genome as a whole.
Table 2 summarizes the genetic events identified in all of the
genome sequences assessed based on comparison to the
prototype strain, Dumas. The differences in insertions and
deletions were primarily due to variability in the reiteration
regions, as discussed below, but it was also noted that many of
the homopolymer stretches located in non-coding regions were
variable between strains as well as within a given strain. The
numbers presented in the table are based on what was
determined to be the consensus sequence for the different
isolates, but as intra-strain variability is also a factor these
numbers are not absolutes.
As was noted for the Oka strains (Gomi et al., 2002), the
reiteration regions were found to vary within a strain as well as
between strains. Fig. 2A illustrates the different subunits
identified in the various reiteration regions and Fig. 2B
summarizes what was found to be the predominant or consensus
form of the individual reiterations for the different strains.
While no specific attempt was made to characterize all of the
different forms of the reiterations within a given strain,
observations made based on the sequence data obtained for
these regions indicated that the extent of variability appeared
similar to what was noted for the pOka and vOka strains.
Reiteration regions R3 and R4 were the most variable within an
individual strain whereas R1, R2 and R5 showed little or no
variations within a strain. In all reiteration regions but R4, new
subunit types were identified.
R1, located in ORF 11, consists of varying copies of in-frame
15 bp and 18 bp elements and the copy number of these
elements was found to be similar to what has been reported
previously (Davison and Scott, 1986; Yoshida et al., 1999).
R2 is located in ORF 14 (glycoprotein C) and consists of
repeating 42-bp subunits followed by a 32-bp partial element
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Table 2
Overview of genetic variations identified between VZV strains based on a
comparison with the reference sequence Dumas
VZV
Strain
Polymorphisms identified a Insertion
(bp) b
Deletion
(bp)b
Genome
size
(bp)
Total Coding Silent Intergenic
Dumas 18 3 9 6 0 0 124,884
BC 42 12 18 12 653 78 125,459
KEL 42 10 21 11 524 33 125,375
MSP 39 5 17 17 70 71 124,883
SD 32 7 13 12 276 73 125,087
03-500 141 37 72 32 614 259 125,239
8 165 42 86 37 700 134 125,450
11 134 35 66 33 614 118 125,380
22 146 41 68 37 144 160 124,868
32p5 37 7 19 11 174 112 124,946
32p22 38 7 20 11 281 82 125,083
32p72 65 26 28 11 328 43 125,169
36 43 10 21 12 190 44 125,030
49 43 11 20 12 219 62 125,041
pOka 188 61 92 35 413 172 125,125
vOka 241 89 110 42 346 152 125,078
VarilRix 239 88 107 44 29 92 124,821
VariVax 227 83 105 39 23 92 124,815
a Polymorphisms indicated for Dumas are for sites where Dumas differed
from all other strains.
b The length of insertions and deletions is primarily due to variability in the
reiteration regions and variation in the length of homopolymer stretches in non-
coding regions.
450 S.D. Tyler et al. / Virology 359 (2007) 447–458copy, with a reported range in the number of major subunits
from 2 to 14 (Grose et al., 2004; Takada et al., 1995). VZV-32
contained the same pattern of 7 subunits in each of the passages
examined, indicating stability within the region during replica-
tion in cell culture. VZV-8 possessed more subunits in R2 (14)
than any other isolate, with all others found to contain between
6 and 9 elements. Yoshida et al. (2003) have speculated that 6 to
9 copies of the 42-bp subunits, which are found in the majority
of VZV isolates, may offer strains an advantage in terms of
virulence to human skin.
R3 is located in ORF 22 and consists of repeating copies of
9 bp elements. Davison and Scott (1986) suggested that R3 may
contain greater than 100 subunit elements in virion DNA,
although no strains as yet have been reported to contain this
many. It is the most variable reiteration region both within an
isolate, as evidenced by the three passages of VZV-32 having
different subunit patterns, and between the isolates. In all strains
R3 was found to end with a 4-bp partial copy of subunit A,
which Davison and Scott (1986) termed ‘X’ (a GCCC motif),
and not the 3-bp motif termed ‘X’ (GGA) that Gomi et al.
(2002) reported at the end of the repeat region.
R4 is located in the duplicated inverted repeats IRS/TRS and
consists of repeating 27-bp elements followed by an 11-bp
partial copy of the element. It has been reported to be unstable
by a number of groups (Ida et al., 2000; Takada et al., 1995;
Takayama and Takayama, 2004) and we observed a relatively
high amount of variation within an isolate, but no attempt was
made to classify all different forms of the region and what is
presented was the form deemed to be the consensus sequence
for this region.
Fig. 2. (A) Nucleotide composition of the subunits that make up the repeat elements in reiteration regions R1 to R5. Variable sites are indicated with an asterisk (*). (B)
Subunit patterns for reiteration regions R1 to R5 for the isolates examined in this study. For reiteration regions that were found to be variable within a given strain only
the predominating or consensus sequence is illustrated.
451S.D. Tyler et al. / Virology 359 (2007) 447–458R5 is located between ORFs 60 and 61 and consists of 88 bp
and 24 bp tandemly arrayed elements that appeared to be stable
within an isolate and during passages in cell culture. In a study
of R5 in Japanese isolates, Yoshida and Tamura (1999) noted
between 2 and 4 copies of the 88-bp element, with 3
predominant. In this comparison only the pOka and vOka
strains showed 3 copies, with all other strains containing just 2
copies. Variation had been previously noted at locations in this
subunit, G/T at base 4, A/G at position 61 and G/A at position
72, and an additional change at position 32 (C/A) was observed
in VZV-36 and VZV-49 but no variability has been observed inthe B subunit (Davison and Scott, 1986; Gomi et al., 2002;
Grose et al., 2004).
Gene-specific variability
In addition to thevariations alreadynoted, regionsof inter- and
intra-strain variation were also observed in numerous other
locations. These were primarily restricted to non-coding inter-
genic regions; however, there were a few notable exceptions.
A T/C polymorphism in the stop codon of ORF 0 from the
three vaccine strains eliminated the termination of this gene and
Table 3
Variability in VZV ORFs organized by frequency of variable sites
ORF a Size (bp) Total SNPsb Coding SNPsb Silent SNPsb Function
No. Per 100 bp No. Per 100 bp No. Per 100 bp
1 327 10 3.06 4 1.22 6 1.83 Membrane protein
62/71 3933 60 1.53 26 0.66 34 0.86 Transactivator, tegument protein
60 480 6 1.25 2 0.42 4 0.83 Envelope glycoprotein L
0 324 4 1.23 1 0.31 3 0.93 Putative transmembrane protein
58 666 7 1.05 4 0.60 3 0.45 HSV-1 UL3 homolog
35 777 8 1.03 3 0.39 5 0.64 HSV-1 UL24 homolog
36 1026 9 0.88 4 0.39 5 0.49 Thymidine kinase
56 735 6 0.82 2 0.27 4 0.54 HSV-1 UL4 homolog
65 309 2 0.65 1 0.32 1 0.32 HSV-1 UL9 homolog
15 1221 7 0.57 2 0.16 5 0.41 HSV-1 UL43 homolog
54 2310 13 0.56 5 0.22 8 0.35 HSV-1 UL6 homolog
37 2526 14 0.55 6 0.24 8 0.32 Envelope glycoprotein H
14 1389 7 0.50 3 0.22 4 0.29 Envelope glycoprotein C
53 996 5 0.50 1 0.10 4 0.40 HSV-1 UL7 homolog
31 2607 13 0.50 7 0.27 6 0.23 Envelope glycoprotein B
33 1818 9 0.50 7 0.39 2 0.11 Protease
16 1227 6 0.49 2 0.16 4 0.33 HSV-1 UL42 homolog; pol processivity
10 1233 6 0.49 4 0.32 2 0.16 Tegument protein; transactivator
29 3615 17 0.47 4 0.11 13 0.36 Single-stranded DNA-binding protein
32 432 2 0.46 2 0.46 0 0.00 Putative substrate for ORF47 kinase
57 216 1 0.46 1 0.46 0 0.00 Function unknown
47 1533 7 0.46 4 0.26 3 0.20 Serine–threonine protein kinase
22 8229 37 0.45 15 0.18 22 0.27 HSV-1 UL36 homolog
21 3117 14 0.45 5 0.16 9 0.29 HSV-1 UL37 homolog
9 909 4 0.44 1 0.11 3 0.33 HSV-1 UL49 homolog
8.5(9A) 228 1 0.44 1 0.44 0 0.00 Envelope protein gN
61 1404 6 0.43 2 0.14 4 0.28 Transactivator, transrepressor
68 1872 8 0.43 6 0.32 2 0.11 Envelope glycoprotein E
48 1656 7 0.42 5 0.30 2 0.12 Deoxyribonuclease
41 951 4 0.42 0 0.00 4 0.42 HSV-1 UL18 homolog
2 717 3 0.42 1 0.14 2 0.28 Function unknown
28 3585 15 0.42 9 0.25 6 0.17 DNA polymerase
39 723 3 0.41 2 0.28 1 0.14 HSV-1 UL20 homolog
12 1986 8 0.40 1 0.05 7 0.35 HSV-1 UL46 homolog
7 780 3 0.38 2 0.26 1 0.13 HSV-1 UL51 homolog
50 1308 5 0.38 1 0.08 4 0.31 Envelope glycoprotein M
67 1065 4 0.38 1 0.09 3 0.28 Envelope glycoprotein I
64/69 543 2 0.37 2 0.37 0 0.00 HSV-1 US10 homolog
52 2316 8 0.35 4 0.17 4 0.17 HSV-1 UL8 homolog; helicase–primase
43 2031 7 0.34 4 0.20 3 0.15 HSV-1 UL17 homolog
55 2646 9 0.34 3 0.11 6 0.23 HSV-1 UL5 homolog; helicase–primase
11 2157 7 0.32 2 0.09 5 0.23 HSV-1 UL47 homolog
38 1626 5 0.31 2 0.12 3 0.18 HSV-1 UL21 homolog
5 1023 3 0.29 0 0.00 3 0.29 Glycoprotein K
17 1368 4 0.29 4 0.29 0 0.00 HSV-1 UL41 homolog
6 3252 9 0.28 5 0.15 4 0.12 HSV-1 UL52 homolog; helicase–primase
20 1452 4 0.28 1 0.07 3 0.21 HSV-1 UL38 homolog
44 1092 3 0.27 1 0.09 2 0.18 HSV-1 UL16 homolog
42/45 2244 6 0.27 1 0.04 5 0.22 HSV-1 UL15 homolog
66 1182 3 0.25 2 0.17 1 0.08 Serine–threonine protein kinase
24 810 2 0.25 1 0.12 1 0.12 HSV-1 UL34 homolog
51 2508 6 0.24 1 0.04 5 0.20 Helicase; origin-binding protein
63/70 837 2 0.24 0 0.00 2 0.24 Tegument protein
4 1359 3 0.22 0 0.00 3 0.22 Transactivator, tegument protein
13 906 2 0.22 1 0.11 1 0.11 Thymidylate synthetase
59 918 2 0.22 1 0.11 1 0.11 Uracil-DNA glycosylase
34 1740 3 0.17 2 0.11 1 0.06 HSV-1 UL25 homolog
19 2328 4 0.17 1 0.04 3 0.13 Ribonucleotide reductase (large subunit)
26 1758 3 0.17 1 0.06 2 0.11 HSV-1 UL32 homolog
46 600 1 0.17 0 0.00 1 0.17 HSV-1 UL14 homolog
40 4191 6 0.14 0 0.00 6 0.14 Major nucleocapsid protein
23 708 1 0.14 0 0.00 1 0.14 HSV-1 UL35 homolog
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Table 3 (continued)
ORF a Size (bp) Total SNPsb Coding SNPsb Silent SNPsb Function
No. Per 100 bp No. Per 100 bp No. Per 100 bp
18 921 1 0.11 0 0.00 1 0.11 Ribonucleotide reductase (small subunit)
27 1002 1 0.10 0 0.00 1 0.10 HSV-1 UL31 homolog
30 2313 2 0.09 0 0.00 2 0.09 HSV-1 UL28 homolog
8 1191 1 0.08 1 0.08 0 0.00 Deoxyuridine triphosphatase (dUTPase)
3 540 0 0.00 0 0.00 0 0.00 HSV-1 UL55 homolog
25 471 0 0.00 0 0.00 0 0.00 HSV-1 UL33 homolog
49 246 0 0.00 0 0.00 0 0.00 HSV-1 UL11 homolog
a For the genes which harbor the reiteration regions, ORFs 11, 14 and 22, variability within the reiterations has not been included.
b In addition to the sites identified in the current strains additional polymorphic sites have been included as referenced in the text.
453S.D. Tyler et al. / Virology 359 (2007) 447–458resulted in the protein being 199 amino acids long as opposed to
107. This change did not occur in pOka or any of the other
isolates. This gene is postulated to be a putative transmembrane
protein and its existence is based solely on computer-based gene
prediction algorithms (GenBank accession NC_001348 for
Human herpesvirus 3, strain Dumas).
A single base deletion in ORF 12 from VZV-32 P72 resulted
in a frameshift that caused the immediate termination of the
reading frame. As a result, the ORF 12 tegument protein from
this strain was 290 amino acids long as opposed to 661 amino
acids. Two independent clones obtained directly from nucleo-
capsid DNA were sequenced and support the deletion.
However, data obtained by sequencing bulk PCR product
over this region indicated that a minority of the virus population
did not possess this deletion (data not shown). This minority of
the population would still produce a full-length functional
protein but in the vast majority this gene would be truncated.
pOka and the three vaccine strains were all found to have two
3-bp (1 codon) deletions, one in ORF 17 that removed S123,
and one in ORF 56 which removed S221. Similarly these strains
were also found to have a 15-bp in-frame deletion in ORF 29
that removed amino acids 1168–1172 (NISGS), and a 3-bp
insertion in ORF 60 which added a methionine residue between
amino acids 9 and 10. Both of the latter variations were also
found in VZV-8. It is interesting to note that the 15-bp deletion
in ORF 29 appeared to represent 1-U of a 2-U tandem repeat
present in the other strains.
It was also noted that pOka and the three vaccine strains all
had a 1-bp insertion upstream of the start of ORF 32 which put
an alternate start codon in-frame with the potential to add an
additional 33 residues to the amino terminal of this protein.
Analysis of the sequence in this region identified appropriately
located potential promoter sequences if the true start codon was
the one found in Dumas. No such signals were found for the
alternative start codon in the Oka derivatives, implying that the
true start was likely the same as that in Dumas. However, it
should be noted that transcription signals could not be predicted
for many of the VZV genes.
A summary of all genes based on SNP frequency is given in
Table 3. In addition to the full genome sequences discussed in
the current report, the analysis of the SNPs was expanded to
include those reported previously in more limited sequence
analysis studies (Barrett-Muir et al., 2001, 2003; Carr et al.,
2004; Faga et al., 2001; Kamiyama et al., 2001; Kinchington etal., 1986; Loparev et al., 2000, 2004; Morfin et al., 1999; Muir
et al., 2002; Wagenaar et al., 2003; Wirgart et al., 2006; Zerboni
et al., 2005).
Aside from the variations identified in the coding sequences
there were other novel insertions/deletions that were found in
non-coding regions that are notable since they appear to be
strain specific.
VZV-22 was found to have a 3-bp insertion (TAT) located
approximately 20 bp downstream of ORF 39 that appeared to be
a duplication of the 3 bp adjacent to it. This was the only strain
found to contain this particular sequence. Immediately following
the stop codon of ORF 49, VZV-8, pOka and the three vaccine
strains were found to share a 10-bp deletion (CCCTGATAAA)
of a sequence present in all other strains examined.
VZV-8, pOka and the 3 vaccine strains were also found to
have a 4-bp insertion (ACAA) located approximately 45 bp
from the end of ORF 62 that also appears as if it is a duplication
of the adjacent 4 bp. VZV-11, VZV-22, VZV-03-500, pOka and
the vaccine strains all have a 3-bp insertion (CAT) approxi-
mately 80 bp upstream of R4. In this case the insertion appeared
to be unique and not a duplication. And lastly, VZV-11, VZV-22
and VZV-03-500 were found to have a single base insertion (C)
located slightly downstream of the ORI sequence. This single
base insertion was minor but was noted as it was present in a
region not associated with typical intra-strain variation (i.e.
homopolymer regions). These last three events were all located
in the long repeat region and therefore were duplicated at
similar locations in the other inverted repeat.
Serial passage of VZV-32 and links to attenuation
Three of the isolates sequenced were derivatives of the same
strain taken at different passage numbers (VZV-32 P5, VZV-32
P22 and VZV-32 P72). Since the original attenuated vaccine
strain was derived via multiple passage of the virus it was
postulated that a correlation might appear between SNPs that
develop during serial passage. Discounting variation in the
reiteration regions, a total of 31 base substitutions were
identified between the different passages, virtually all of
which appeared between passages 22 and 72. Of these, only
five were found outside of ORFs 62/71, the IE62 gene. Two
were in non-coding regions and two were silent mutations, one
in ORF 44 and one in ORF 61. Only one coding mutation was
found outside of the IE62 gene, and this was in VZV-32 P72
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substitution H291R. This variation was unique to this strain and
did not correlate with any of those identified in the vaccine
strains.
In total, 13 variable sites were identified in IE62, of which
seven were silent mutations or polymorphic sites that were a mix
of the wild-type and variable base at that position. In all cases
these were only detected in VZV-32 P72. Of particular interest
were the amino acid substitutions S628G, R958G and I1260V, as
these are found in the three vaccine strains but not in pOka. A
comparison of the IE62 sequences from the VZV-32 passages
with pOka and the vaccine strains is presented in Table 4. The
virulence status of VZV-32 P72 with respect to attenuation is
unknown. However, co-evolution of variable sites suggests the
genes in which these variations have occurred were significant
and these changes become more interesting considering the
stability of the VZV genome as a whole.
In addition to IE62, recent studies of an Oka vaccine strain
have implicated other genes with links to attenuation and thoseTable 4
Variable sites identified in ORF 62/71 (IE62) between the different serial passages of
from it, vOka, VarilRix and VariVax
Nucleotide a
Position 32p5 32p22 32p72 pOka vOka
183 C T T
296 T Y
387 T C C
1023 A G
1206 A R
1337c T Y
1419 A G G
1527 G T T
1535 T Y
1548 A G G
1827 A G G
1882 A G G
1969 G A A
1998 A G
2064 A G
2303 A R
2424c T Y
2637 A R
2872 A G G
3133 A G
3170 A R
3215 A R
3429 A G
3435 A G
3590 T C
3622 T G G
3644 A G
3683 T C C
3721 A G
3778 A G G
3822 T C C
3824 T Y
The locations at which all three vaccine strains develop coding mutations not shared w
32p72 are indicated in bold.
a Polymorphic sites are designated by a Y for T/C and R for A/G.
b In cases where polymorphic sites give rise to an alternate coding sequence bot
c Variable site described by Gomi et al. (2000) not reflected in the full genome sinvolved were localized to the region containing ORFs 30 to 55
(Zerboni et al., 2005). This comparative analysis was therefore
extended to focus exclusively on this region. No common
variations were noted between the serial passages of VZV-32
and the vaccine strains examined and in fact the degree of
variability in this region among the vaccine strains studied was
less extensive than that reported. The specific variations noted
between pOka and the vaccine strains are summarized in Table 5.
Discussion
This analysis of multiple VZV genomes has been informa-
tive on many fronts and has provided further insight into
differences associated with cell spread and virulence between
various VZV strains. In addition to developing a better
understanding of structural features within the VZV genome,
the comparison has revealed that one feature with potential
implications for replication efficiency is likely not a significant
contributor to attenuation, namely the origin of replication. InVZV-32 when compared to pOka and the three attenuated strains that are derived
Amino acid
VarilRix VariVax Position Dumas Variation b
T T 61 H H
Y Y 99 M M/T
C C 129 L L
G G 341 P P
402 S S
446 L L/P
G G 473 A A
T T 509 T T
Y 512 V V/A
G G 516 V V
G G 609 R R
G G 628 S G
A A 657 A T
G R 666 A A
688 P P
768 Q Q/R
808 A A
879 G G
G G 958 R G
1045 K E
1057 Q Q/R
1072 Q Q/R
G G 1143 A A
1145 P P
C C 1197 V A
G G 1208 S A
1215 Q R
C C 1228 L P
1241 S G
G G/R 1260 I I/V
C C 1274 G G
Y/C Y 1275 L L/S
ith pOka are shaded and of those the ones found to have also developed in VZV-
h potential amino acids have been indicated.
equence.
Table 5
Vaccine strain-specific variable sites identified in the ORF30-55 region
ORF Function a Amino acid location Amino acid and codon change
vOka VarilRix VariVax
31 Glycoprotein gB I530 I-(I/V) ATT-RTT I-(I/V) ATT-RTT I-VATT-GTT
39 Integral membrane protein; role in virion egress M207 M-T ATG-ACG M-T ATG-ACG M-(M/T) ATG-AYG
48 Deoxyribonuclease; role in maturation/packaging T310 T-(T/A) ACG-RCG T-(T/A) ACG-RCG
50 Glycoprotein gM S193 S-(S/G) AGT-RGT
52 Component of helicase–primase complex I15 I-(I/V) ATT-RTT I-(I/V) ATT-RTT
55 Component of DNA helicase–primase complex; helicase V495 V-(V/A) GTT-GYT
55 Component of DNA helicase–primase complex; helicase A585 A-(A/T) GCC-RCC A-(A/T) GCC-RCC A-(A/T) GCC-RCC
55 Component of DNA helicase–primase complex; helicase C601 C-(C/R) TGT-YGT C-(C/R) TGT-YGT
a As stated in Kingchington and Cohen, 2000. For ORF 39 the putative function has been taken from GenBank entry NC_001348, human herpesvirus 3 (strain
Dumas) as none is available in the literature.
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relatively immutable within a given genus (Tyler et al., 2005)
so it would seem to follow that variability in this region could
have important implications on replication. The initial
observations that variability was present in the vaccine strains
has lead to the speculation that variation in the core motif of
the ORI region may be associated with virulence and
pathogenicity (Grose, 2005). However, based on the observa-
tions presented here there does not appear to be any link
between this sequence and the manifestation of disease as this
region appears to be variable within a given strain as well as
between strains. However, further studies will be needed to
determine if these differences do in fact affect the replication
of the virus and hence the severity or rate of progression of
disease.
Other possible roles for the origin of replication in virulence
could be implicated by changes in ORF 51, the origin-binding
protein (OBP) or in the OBP domains within the ORI region. The
VZV origin was originally reported to consist of a 46-bp
palindromic sequence centering around 16 TA dinucleotide
repeats, along with three sites recognized by the origin-binding
protein (OBP) (Stow and Davison, 1986). These 3 sites, termed
A (CGTTCGCACT, 110,179–110,188 bp), B (CGTTCGCACT,
110,002–110,011 bp) and C (CATTCGCACT, 110,118–
110,127 bp) are located upstream of the TA/GA motifs and
experimental data suggest that a minimal VZVorigin consists of
the TAmotifs and binding site A (Stow et al., 1990).While some
variation was noted in the OBP among the strains, only one
coding mutation was identified and none of the 18 isolates
studied exhibited any coding mutations in the carboxyl terminus
of the OBP, which has been identified as containing the
sequence-specific binding activity (Chen and Olivo, 1994).
Some variation was noted in the predicted binding domain
sequences but this was restricted to a single G/A substitution in
the second position of binding site B and appears to be more
related to strain variation or the phylogenetic relationship
between the isolates. In addition, a number of variations were
noted among the 7 genes associated with the replication
complex. However, with the exception of the vaccine deriva-
tives, none of the strains involved in this study are known to
exhibit reduced clinical levels of virulence or appear to be
impeded in their ability to replicate, so it is assumed that thesedifferences do not affect replication, or at least impose a minimal
impact on the viruses.
The strains VZV-MSP and VZV-BC, with identical muta-
tions in the gE domain, exhibit a faster cell spread phenotype
than typical wild-type VZV isolates (Santos et al., 2000). The
initial sequencing of these strains could not definitively rule out
other potential coding changes that might also contribute to the
phenotype displayed (Grose et al., 2004). However, this wider
strain comparison indicates that the only polymorphism that is
unique to and exclusively found in these two strains is the gE
mutation. Based on the assessment of this larger group of strains
it becomes quite clear that these two mutant strains have arisen
independently rather than representing a distinct subgroup of
circulating strains. The implication of this change is as yet
unknown but it is worth noting the recent discovery of two
additional gE mutant viruses which possess a different mutation
in the gE gene (Wirgart et al., 2006), as well as the report of a
third gE mutant which was associated with a fatal case of
hepatitis (Natoli et al., 2006). In all cases the mutations affects
the ecto domain and epitope targeted by mAb 3B3 and may
indicate an important functional significance to this region.
While most SNP-based studies have focussed on the
glycoprotein genes on the assumption that they are likely
candidates for possessing variable sites, this analysis revealed
that they are not necessarily the most variable genes. The initial
analysis identified a number of genes with high numbers of
variable sites, but this observation was somewhat biased by
their relatively large sizes (as is the case with the glycoprotein
genes). When the analysis was refined to take into account the
physical size of the coding regions, a number of other genes
were identified. Many of these are also membrane associated
and such variability may be indicative of immunological
pressures playing a role in the evolution of VZV. In other
cases, such as ORF 35 (nuclear protein), ORF 36 (thymidine
kinase), ORF 58 (unnamed protein product, HSV UL3
homolog) as well as IE62, it is more difficult to explain the
degree of variability observed based solely on external
influence; the thymidine kinase pathway is, however, the target
of anti-viral drugs such as acyclovir (Biron et al., 1982; Roberts
et al., 1991).
When VZV-MSP was examined in the SCIDhu mouse model
of VZV pathogenesis, the virus destroyed the human skin
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wild-type isolates (Santos et al., 2000). Thus, VZV-MSP would
appear to have attributes compatible with increased virulence
and it is likely that similar gE mutants would behave the same.
As noted, VZV-MSP and VZV-BC do not exclusively share
SNPs other than the G/A polymorphism in ORF 68 and the two
do not have any unusual SNPs in the seven ORFs in the VZV
replication complex. Thus, it seems increasingly likely that the
faster cell spread phenotype is determined mainly by the single
mutation in the gE ecto domain.
On the other hand, the VZV vaccine strains have the opposite
phenotype in that they spread more slowly in cell culture and in
the skin implants in the SCIDhu mouse model (Moffat et al.,
1998). In an attempt to define the regions of the genome most
likely involved in this phenotype, Zerboni et al. (2005)
performed an informative series of experiments with recombi-
nant viruses produced from overlapping fragments of VZV
genomic DNA in cosmid vectors. Two sets of cosmids were
used to produce chimeric viruses, one from wild-type (parental)
VZV DNA and a second from varicella vaccine DNA. The
results of this study indicated that attenuation appears to be
multi-factorial and also linked mainly to the region comprising
ORFs 30 to 55 with ORFs 31, 33, 35–39, 44, 48, 51, 52, 54
containing a total of 18 mutations which could potentially be
implicated. In contrast, analysis of this region between pOka
and the vaccine strain sequences used in this study identified
only eight substitutions affecting the amino acid sequences that
were present in at least one of the vaccine strains but not in
pOka with the affected genes being restricted to ORFs 31, 39,
48, 50, 52 and 55. In virtually all cases these substitutions were
also identified as polymorphic sites that did not definitively
change the coding sequence of the viral population and/or were
not universally present in all of the vaccine strains. These
differences are consistent with those reported by Gomi et al.
(2002) but differ from what was found by Zerboni et al. (2005).
The original viruses and sequence data employed by Zerboni et
al. are described as being based on the Merck consensus
sequence for the vaccine Oka and the Yaminishi consensus
sequence for the parent Oka, and therefore these should be
analogous to the sequences for VariVax and the pOka strains.
However, as indicated below, there appear to be other
inconsistencies with the variations that they encountered
between the parental and vaccine versions of the Oka strains
and those that are presented in the published or publicly
available versions. It is known that the current attenuated
vaccine stocks are in fact mixed populations of viruses and not
pure strains (Gomi et al., 2000), so it is likely that some of the
discrepancies could be attributed to the fact that in constructing
the cosmid clones only a single representative of the population
was selected. In short, the phenotypes that are reported for the
vaccine and parental strains used by Zerboni et al. in the animal
model are of interest, but the sequences of the viruses are not
consistent with the prototypic vaccine strains present in
GenBank.
Zerboni et al. (2005) state in their results that sequencing
of ORF62/71 from the pOka and vOka cosmids identified
only two amino acid changes in vOka compared to pOka.However, as is evident in Table 4, this is not consistent with
what is found in the publicly available sequences of pOka
and the vaccine derivatives. The R958G variation cited is
found in vOka, VarilRix and VariVax as well as in VZV-32
P72. However, the Y1058H substitution appears to be unique
to the strain described by Zerboni et al. (2005). Similarly the
3 amino acid changes subsequently listed for IE62 in the
comparison of consensus sequence data for pOka and vOka
(A657T, S1208A and L1228P) are all found in the published
pOka sequence and each of the three vaccine derivatives.
Coincidentally these substitutions appear to correspond to
variations that differ between VZV-Dumas and the Oka-
based strains. The differences noted here could conceivably
affect the activity of IE62 and subsequently the phenotype of
the resulting chimeras. Specifically the residues at positions
99, 628, 958, 1197, 1260 and 1275 are all of interest as they
are consistently different between pOka and the vaccine
strains, although some result in polymorphic amino acid
substitutions due to the mixed population present in the
vaccine stocks.
In spite of these conflicting observations, data are building,
which appears to support the theory that variations in IE62
alone may not be solely responsible for attenuation and that it
is a convergence of differences in the vaccine strains that is
responsible. A recent study by Cohrs et al. (2006) looking at
transcriptional differences between pOka and vOka found that
transcription levels of ORFs 62, 65, 66 and 67 were all
significantly suppressed in vOka infected cells. All of these
genes are relevant to the assembly and spread of the virus and
it may be a cascade effect of multiple factors that ultimately is
responsible for attenuation. However, with the overall stability
of the VZV genome it is likely that a limited number of key
mutations will be responsible, and as is evident with the gE
mutants, even a single amino acid substitution can have a
dramatic effect on the behavior of the virus. A similar
situation has also been observed in equid herpesvirus 1,
another Varicellovirus, where a single amino acid substitution
in the DNA polymerase gene was found to be strongly
associated with neurological versus non-neurological disease
outbreaks (Nugent et al., 2006). Thus, this initial assessment
of VZV genomic cartography not only demonstrates the
degree of diversity that exists among isolates, but also
suggests that more VZV genomic variants will be isolated in
the future.
Methods and materials
Viruses and genome sequences
We have recently reported on the sequencing of 11 new VZV
genomes (Peters et al., 2006). All of the newly sequenced
strains were of North American origin with three originating in
the United States, SD (South Dakota), KEL (Iowa) and VZV-32
(Texas) and the remainder being from Canada, VZV-03-500
(Alberta) and VZV-8, VZV-11, VZV-22, VZV-36 and VZV-49
(New Brunswick). In order to evaluate mutations that can occur
during serial passage of VZV, the isolate VZV-32 was
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passages 5, 22 and 72.
Sequencing of these isolates was performed essentially as
previously described for VZV-MSP and VZV-BC (Grose et al.,
2004; Peters et al., 2006). Briefly, two approaches were taken.
One involved the construction of EcoRI-restricted VZV
genomic libraries. Following the isolation of clones representing
the various regions of the genome, sequencing was performed
using a panel of custom primers spanning the entire genome.
Alternatively, shotgun libraries of the genomic DNA were
constructed and the resulting random library clones were end
sequenced using universal primers flanking the cloning site with
specific PCR products being amplified and sequenced in order to
close gaps and resolve problem areas.
In addition, PCR primers were designed to generate
amplicons spanning the junction of the genome during its
replicative phase (ORF 0 to ORF 62) in order to obtain data
for the terminal regions. The terminal sequences were further
characterized from linear nucleocapsid DNA by ligating on a
custom adaptor followed by PCR using adaptor-specific and
VZV-specific primers targeting either end. In all cases where
direct sequencing of the PCR products indicated that
multiple sequences were present, these amplicons were
cloned and several independent clones were subsequently
sequenced.
Sequence analysis
In addition to the VZV genome sequences mentioned above,
the analysis included the sequences of the prototype strain VZV-
Dumas (Davison and Scott, 1986), VZV-Oka, parental and
vaccine strains (Gomi et al., 2002), VZV-MSP and VZV-BC
(Grose et al., 2004) as well as the sequences from the
commercially produced VZV vaccine strains VariVax and
VarilRix (Vassilev, 2005). The Virus Bioinformatics Resource
at http://www.virology.ca (Esteban et al., 2005) was used
extensively in the analysis of the data. The annotated genomes
were entered into Viral Orthologous Clusters in order to analyze
the gene products, while the aligned genomes were analyzed in
Base-By-Base to identify polymorphic sites and amino acid
changes. Phylogenetic analysis was conducted using MEGA
v3.1 (Kumar et al., 2004) using Neighbour-Joining with 500
bootstrap replicates. The Kimura 2-parameter model was
employed with complete deletion of gaps or missing data.
Additional alignments and comparisons were also performed
using MEGA and ClustalW.
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